Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Lichen simplex chronicus

Dermatology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Escalate

Urgently assess rapidly progressive pain, ulceration, purpura, systemic illness, severe genital symptoms, neurological deficit or a suspicious solitary plaque rather than attributing every symptom to habitual scratching.

Synopsis

Recognise lichenification as the product of repeated rubbing, identify the initiating itch and psychosocial amplifiers, and break the itch-scratch cycle without missing infection or malignancy.

  • Lichen simplex is a thick leathery plaque with exaggerated skin markings caused and maintained by repeated rubbing or scratching.
  • Common accessible sites include nape, forearms, ankles, lower legs, scalp and anogenital skin; one person may have several plaques.
  • Find the itch source: eczema, contact allergy, tinea, scabies, venous disease, neuropathy and systemic pruritus may initiate the cycle.
  • Break scratching with explanation, nail care, night barriers, emollient and a short adequately potent topical corticosteroid matched to site.
  • Address stress and automatic behaviour respectfully; behavioural techniques complement physical treatment and do not imply the itch is imagined.
  • Biopsy a persistent atypical, ulcerated or indurated plaque and sample a fungal edge when tinea remains plausible.
  • For Lichen simplex chronicus, document body sites, severity, sleep and function, recent treatment, infection features and what the patient can realistically apply each day.
  • In Lichen simplex chronicus, reassess the diagnosis when a well-used, correctly potent regimen fails rather than repeatedly intensifying treatment without examining adherence, exposure and mimics.

Key red flags

Non-healing ulcer, bleeding induration, widespread severe pruritus with systemic symptoms, genital scarring, neuropathic deficit, child safeguarding concern or treatment-resistant focal disease requires specialist evaluation.

Atypical tumour warning

Progressive induration, ulceration, bleeding or non-response despite verified treatment requires biopsy assessment.

Investigation priorities

01
Full skin, nail and mucosal examinationFirst step

Identify the primary itch disorder and other plaques beyond the presenting site.

Management branches

Typical focal plaqueInterrupt the itch-scratch cycle

A stable accessible lichenified plaque lacks infection, tumour features or a clear untreated mimic.

  1. Explain the reinforcement cycle, agree a non-shaming strategy such as short nails, covering at night and substituting pressure or cooling for scratching.
  2. Apply a potent topical corticosteroid thinly for a defined short course and use generous emollient to reduce dryness and friction.
  3. Review itch, thickness and actual scratching triggers within two to four weeks, then step down anti-inflammatory exposure.

Key medicines

Betamethasone valerate 0.1% creamApply thinly to an active body-site plaque once or twice daily for up to four weeks, then reduce or stop as skin flattens and itch settles.Avoid face, genitals, folds, infection and unplanned occlusion; monitor atrophy and systemic exposure and biopsy rather than extending ineffective use.
Clobetasol propionate 0.05% ointmentAdults apply thinly once or twice daily only to severe resistant thick plaques under specialist direction, not exceeding four weeks or 50 g weekly.Never use on thin anogenital or facial skin without specialist instruction; avoid untreated infection and prolonged occlusion and step down as soon as control permits.
Open full textbook →Answer 2 questions
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • British Association of Dermatologists lichen simplexItch-scratch cycle, underlying causes and treatment.
  • British Association of Dermatologists topical corticosteroidsPotency, quantity, safe use and adverse effects.
  • Betamethasone valerate 0.1 percent cream SmPCPotent topical corticosteroid regimen and safeguards.
  • Clobetasol propionate 0.05 percent ointment SmPCVery potent corticosteroid limits and safety requirements.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom